These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 16454534

  • 1. Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability?
    Shear NH.
    Drug Saf; 2006; 29(1):49-66. PubMed ID: 16454534
    [Abstract] [Full Text] [Related]

  • 2. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ, Bello-Quintero CE.
    J Manag Care Pharm; 2004; 10(4):318-25. PubMed ID: 15298530
    [Abstract] [Full Text] [Related]

  • 3. Treatments for psoriasis and the risk of malignancy.
    Patel RV, Clark LN, Lebwohl M, Weinberg JM.
    J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
    [Abstract] [Full Text] [Related]

  • 4. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options.
    Leon A, Nguyen A, Letsinger J, Koo J.
    Expert Opin Pharmacother; 2007 Apr; 8(5):617-32. PubMed ID: 17376017
    [Abstract] [Full Text] [Related]

  • 5. Biologicals in the treatment of psoriasis.
    Boker A, Kimball AB, Rolz-Cruz G.
    Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
    [Abstract] [Full Text] [Related]

  • 6. Combining traditional agents and biologics for the treatment of psoriasis.
    Cather JC, Menter A.
    Semin Cutan Med Surg; 2005 Mar; 24(1):37-45. PubMed ID: 15900797
    [Abstract] [Full Text] [Related]

  • 7. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
    Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP.
    Ned Tijdschr Geneeskd; 2006 May 13; 150(19):1065-70. PubMed ID: 16733982
    [Abstract] [Full Text] [Related]

  • 8. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.
    Weger W.
    Br J Pharmacol; 2010 Jun 13; 160(4):810-20. PubMed ID: 20590580
    [Abstract] [Full Text] [Related]

  • 9. Biologic agents in the treatment of psoriasis.
    Guarneri F, Guarneri C, Guarneri B.
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov 13; 1(3):193-217. PubMed ID: 19075983
    [Abstract] [Full Text] [Related]

  • 10. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A.
    Cutis; 2009 Oct 13; 84(4 Suppl):14-24. PubMed ID: 19916298
    [Abstract] [Full Text] [Related]

  • 11. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG, Gupta AK, Cherman AM, Inniss KA.
    J Cutan Med Surg; 2007 Oct 13; 11(3):99-122. PubMed ID: 17511926
    [Abstract] [Full Text] [Related]

  • 12. [Long-term control of psoriasis is necessary].
    Sánchez Carazo JL, Martínez Casimiro L, Alegre de Miguel V.
    Actas Dermosifiliogr; 2008 Jan 13; 99 Suppl 1():29-36. PubMed ID: 18341851
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A.
    Br J Dermatol; 2008 Aug 13; 159(2):274-85. PubMed ID: 18547300
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
    Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A, Gualdi G, Guarneri C, Borsari S, Cassano N.
    Acta Derm Venereol; 2014 May 13; 94(3):293-7. PubMed ID: 24158307
    [Abstract] [Full Text] [Related]

  • 15. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost.
    Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J.
    Expert Opin Pharmacother; 2003 Sep 13; 4(9):1525-33. PubMed ID: 12943482
    [Abstract] [Full Text] [Related]

  • 16. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM, Bottino CJ, Lindholm J, Buchholz R.
    J Drugs Dermatol; 2005 Sep 13; 4(5):544-55. PubMed ID: 16167412
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A, Talamonti M, Botti E, Spallone G, Papoutsaki M, Chimenti S.
    Dermatology; 2009 Sep 13; 219(1):48-53. PubMed ID: 19372639
    [Abstract] [Full Text] [Related]

  • 18. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
    Tzu J, Kerdel F.
    Dermatol Ther; 2008 Sep 13; 21(2):131-41. PubMed ID: 18394087
    [Abstract] [Full Text] [Related]

  • 19. [Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
    Sánchez-Regaña M, Dilmé E, Puig L, Bordas X, Carrascosa JM, Ferran M, Herranz P, García-Bustinduy M, López Estebaranz JL, Alsina M, Rodríguez MA, Ribera M, Fernández-López E, Moreno JC, Belinchón Romero I, Vidal D, Grupo Español de Psoriasis de la Academia Española.
    Actas Dermosifiliogr; 2010 Mar 13; 101(2):156-63. PubMed ID: 20223158
    [Abstract] [Full Text] [Related]

  • 20. Biological agents in the treatment of psoriasis.
    Tzu J, Krulig E, Cardenas V, Kerdel FA.
    G Ital Dermatol Venereol; 2008 Oct 13; 143(5):315-27. PubMed ID: 18833073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.